Login / Signup

Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).

Richard F PollockSimon R HellerThomas R PieberVincent WooJens GundgaardNino HallénMaria LuckevichDeniz TutkunkardasBernard Zinmannull null
Published in: Diabetes, obesity & metabolism (2019)
Over a 2-year period, degludec improved clinical outcomes at a lower cost as compared to glargine U100 in patients with T2D at high risk of cardiovascular events and hypoglycaemia.
Keyphrases
  • cardiovascular events
  • coronary artery disease
  • cardiovascular disease
  • type diabetes
  • adipose tissue